Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | TMPRSS4 | Q9NRS4 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.52 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.52 |
| ▸ | P2RX1 | P51575 | 2/20 | 0.49 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.49 |
| ▸ | GPR27 | Q9NS67 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | FLT1 | P17948 | 2/20 | 0.49 |
| ▸ | FLT4 | P35916 | 2/20 | 0.49 |
| ▸ | KDR | P35968 | 2/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1663288 | 0.84 | KCNMA1 (0.60) | MEN1KMT2AMAPTP2RX1POLB | |
| SCHEMBL1663714 | 0.80 | MEN1 (0.54) | MEN1KMT2AMAPTLMNAHTT | |
| SCHEMBL8488311 | 0.78 | VCAM1 (0.63) | MEN1KMT2AMAPTVCAM1 | |
| SCHEMBL1662861 | 0.78 | NPC1 (0.58) | MEN1KMT2AMAPTLMNAHTT | |
| SCHEMBL6591721 | 0.77 | P2RX1 (0.64) | MEN1KMT2AMAPTP2RX1ALDH1A1 | |
| SCHEMBL30236947 | 0.77 | MAPT (0.78) | MEN1KMT2AMAPTLMNAHTT | |
| SCHEMBL5226448 | 0.77 | MAPT (0.78) | MEN1KMT2AMAPTLMNAHTT | |
| SCHEMBL10246421 | 0.77 | MEN1 (0.59) | MEN1KMT2AMAPTLMNAPOLB | |
| SCHEMBL1886794 | 0.75 | VCAM1 (0.58) | MEN1KMT2AMAPTTSHRVCAM1 | |
| SCHEMBL5540980 | 0.75 | VCAM1 (0.59) | MEN1KMT2AMAPTLMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130261130-A1 | NEUROTRYPSIN INHIBITORS | NEUROTUNE AG (CH) | 2013-10-03 | — | — | US | disclosed |
| US-20130261130-A1 | NEUROTRYPSIN INHIBITORS | NEUROTUNE AG (CH) | 2013-10-03 | — | — | US | disclosed |
| WO-2012059442-A2 | NEUROTRYPSIN INHIBITORS | NEUROTUNE AG (CH) | 2012-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130261130-A1 | NEUROTRYPSIN INHIBITORS | MTPN, CHRNA7, CHRNA10 | MEN1 3294/4885KMT2A 3851/4885TMPRSS4 232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.